Abstract
Clarithromycin (CTM) is a semisynthetic derivative of erythromycin that have been reported to exhibit potential antibiotic activities mostly against the gram-negative and gram-positive bacteria, lower/upper respiratory tract and skin infection causing pathogens. It is widely used for the prevention and management of infections due to Mycobacterium avium complexes and peptic ulcers due to Helicobacter pylori. Various marketed formulation of CTM in the form of tablets, capsules and other conventional dosage forms is available as anti-infective, however the drug itself has several limitations. These limitations include low oral bioavailability, rapid metabolism, poor targeting to infected sites and toxicity to normal cells/tissues. Also, the CTM-based therapy has been reported for several gastrointestinal adverse effects, including diarrhea, stomach upset, gastric distress, atypical taste, and others. Thus, to overcome these issue, various novel strategies including nanotechnology or nanocarrier-based approaches have showed significant effects and have been immensely considered worldwide. In recent years, the various nanocarriers or nanocarrier-based delivery systems, particularly the polymeric nanocarrier have played significant role in effective drug targeting. Thus, in this review, the various polymeric nanocarrier-based delivery systems of CTM that effective reduced the dosing frequency, improved the patient compliance and potentially enhanced the therapeutic efficiency of CTM has been summarized.
Publisher
Lattice Science Publication (LSP)
Reference24 articles.
1. Van Nuffel, A.M.; Sukhatme, V.; Pantziarka, P.; Meheus, L.; Sukhatme, V.P.; Bouche, G. Repurposing drugs in oncology (ReDO)-clarithromycin as an anti-cancer agent. E Cancer. Med. Sci. 2015, 9, 1-26. [CrossRef]
2. Lebel, M. Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin. Can. J. Infect. Dis. 1993, 4, 148-152. [CrossRef]
3. Hardy, D.J.; Swanson, R.N.; Rode, R.A.; Marsh, K.; Shipkowitz, N.L. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Clement JJ Antimicrob Agents Chemother. 1990, 34(7):1407-13. [CrossRef]
4. Valizadeh, H.; Mohammadi, G.; Ehyaei, R.; Milani, M.; Azhdarzadeh, M.; Zakeri-Milani, P.; Lotfipour, F. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Die Pharmazie, 2012, 67(1), 63-68.
5. Zakeri-Milani, P.; Islambulchilar, Z.; Majidpour, F.; Jannatabadi, E.; Lotfipour, F.; Valizadeh, H. A study on enhanced intestinal permeability of clarithromycin nanoparticles. Braz. J. Pharm. Sci. 2014, 50, 121-129. [CrossRef]
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献